Core Capital Management & Research, inc.’s Fennec Pharmaceuticals FENC Stock Holding History

Core Capital Management & Research, inc.’s Portfolio FENC Stock Details FENC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.72K	Buy	+861	New	+$7.03K	0.01%	160

Other funds holding FENC

Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

SCM

Solas Capital Management Darien, Connecticut $187M AUM 12.91% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PCA

Prospect Capital Advisors Sausalito, California $220M AUM 60.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Core Capital Management & Research, inc.'s FENC Position: Q2 2026 in Review

Core Capital Management & Research, inc. opened a new position in Fennec Pharmaceuticals (FENC) in Q2 2026: 861 shares worth $9.72K. The stake represents 0.01% of the portfolio and ranks #160 among its holdings.

105 funds tracked by Wall St. Rank hold FENC as of Q2 2026.

Core Capital Management & Research, inc. held 861 shares of Fennec Pharmaceuticals worth $9.72K as of Q2 2026.
Fennec Pharmaceuticals was a new Core Capital Management & Research, inc. position in Q2 2026.
Fennec Pharmaceuticals made up 0.01% of Core Capital Management & Research, inc.'s portfolio in Q2 2026, its #160 holding.
105 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2026.

Based on Core Capital Management & Research, inc.'s 13F filing for Q2 2026, filed 9 Sep 2026.